A Prospective, Randomized, Double-Masked, Vehicle Controlled, Phase 2 Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Elamipretide (MTP-131) Topical Ophthalmic Solution in Subjects With Leber's Hereditary Optic Neuropathy (LHON)

Trial Profile

A Prospective, Randomized, Double-Masked, Vehicle Controlled, Phase 2 Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Elamipretide (MTP-131) Topical Ophthalmic Solution in Subjects With Leber's Hereditary Optic Neuropathy (LHON)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Elamipretide (Primary)
  • Indications Leber's hereditary optic atrophy
  • Focus Adverse reactions
  • Acronyms ReSIGHT
  • Sponsors Stealth BioTherapeutics
  • Most Recent Events

    • 04 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 31 Mar 2017 Time frame of primary end point has been changed from assessed at each visit from Baseline to Week 40 to Assessed at each visit from Baseline to Week 56.
    • 31 Mar 2017 Planned End Date changed from 1 Aug 2017 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top